Acetazolamide-Responsive Episodic Ataxia Linked to Novel Splice Site Variant in FGF14 Gene

Cerebellum. 2019 Jun;18(3):649-653. doi: 10.1007/s12311-018-0997-3.

Abstract

Here we describe the case of a patient with episodic dizziness and gait imbalance for 7 years and a negative family history. On clinical examination, interictally, the patient presented with gaze-evoked nystagmus and rebound nystagmus and slight dysarthria. MRI of the brain was normal and peripheral-vestibular function was bilaterally intact. Based on genetic testing (episodic ataxia panel), a heterozygote splice site variant in intron 1 of the FGF14 gene was identified. This report adds important new evidence to previous observations that pathogenic variants in the FGF14 gene may result in variable phenotypes, either in progressive spinocerebellar ataxia (type 27) or in episodic ataxia as in our case. Our patient responded well to acetazolamide (reduction in the frequency of attacks by about two thirds), supporting the hypothesis of a sodium channelopathy.

Keywords: Cerebellum; Channelopathy; Drug treatment; Haploinsufficiency; Hereditary ataxia.

Publication types

  • Case Reports

MeSH terms

  • Acetazolamide / therapeutic use*
  • Adult
  • Anticonvulsants / therapeutic use*
  • Fibroblast Growth Factors / genetics*
  • Humans
  • Mutation
  • Spinocerebellar Degenerations / drug therapy*
  • Spinocerebellar Degenerations / genetics*

Substances

  • Anticonvulsants
  • fibroblast growth factor 14
  • Fibroblast Growth Factors
  • Acetazolamide

Supplementary concepts

  • Spinocerebellar ataxia 27